

**IBN HERBALS**

(A Unit of Curetech Formulations (P) Ltd.)

Khasra no.63, Village-Juddi Kalan, Baddi-173205 (H.P.)

CERTIFICATE OF ANALYSIS (FINISHED PRODUCT)

Product Name	PAINHEAL MR	A.R. No	IBNFP-1701/24
Generic Name	Diclofenac sodium, Paracetamol And Chlorzoxazone Tablets	Batch No.	IACR24002
Mfg. Date	AUG.2024	Exp. Date	JUL.2026
Receiving Date	29.09.2024	Released Date	01.10.2024
Batch Size	5.0 Lac	Sample Qty.	80TABS

TEST	SPECIFICATION	RESULTS
Description:	Quinoline Yellow coloured, elongated, biconvex, uncoated tablets, having scored on one side and plain on other side.	Quinoline Yellow coloured, elongated, biconvex, uncoated tablets, having scored on one side and plain on other side
Identification By Assay: (Diclofenac sodium, Paracetamol, Chlorzoxazone)	In assay, The retention time of the major peaks in the chromatogram of the sample solution corresponds to that of the major peaks of Paracetamol, Diclofenac sodium and Chlorzoxazone in the chromatogram of the standard solution.	In assay, The retention time of the major peaks in the chromatogram of the sample solution corresponds to that of the major peaks of Paracetamol, Diclofenac sodium and Chlorzoxazone in the chromatogram of the standard solution.
Average weight:	0.9500 gM \pm 3% [NLT 0.9215 gm, NMT 0.9785gm]	0.9494 gm
Uniformity of weight:	Not more than two of the individual tablet weights deviate from the average weight by more than \pm 5.0% and none deviates by more than \pm 10.0%	Min: -1.64% Max: +0.96%
Friability:	Not more than 1.00 % w/w	0.35 % w/w
Hardness:	Not less than 5.00 kgf	Min: 09.40 kgf, Max: 13.85kgf
Disintegration:	Not more than 15 minutes	03 Minutes 37 Seconds
Assay: Each uncoated tablet contains:	Limit (%)	Result (mg) (%)
Diclofenac Sodium IP.....50 mg	Not less than 45.00 mg & Not more than 55.00mg	49.66mg 99.3%
Paracetamol IP.....325mg	Not less than 292.5 mg & Not more than 357.5mg	316.10mg 97.3 %
Chlorzoxazone USP.....250 mg	Not less than 225.0 mg & Not more than 275.0 mg (Not less than 90.00 % & Not more than 110.0 % of the Label claim)	251.78mg 100.7%

Remark: In the opinion of the under signed, above sample complies as per In house specifications.

Prepared By	Checked by	Approved By
Date 01/10/2024	Date 01.10.2024	Date 01/10/2024

Format No: SOP/QG/029/F01